GSK to challenge Merck's Gardasil in comparison trial

01/18/2007 | Forbes

GlaxoSmithKline says it plans to test its Cervarix vaccine to prevent cervical cancer against Merck's Gardasil in a gamble for GSK to try to overtake Merck sales. GSK said it would conduct a 1,000-patient trial comparing the two drugs, even though Gardasil already is on the market and Cervarix is not expected to be submitted to the FDA for approval until 2009. The American Cancer Society today is expected to announce its recommendation that HPV vaccinations be routine for all girls as young as 11.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD